Global Edition
Global Edition
UK Edition
EU Edition
US Edition

Understand the story, not the spin.

Markets

FDA Requires Eye Risk Warning on GLP-1 Drug Labels

Published 19 November 2026 · All stories from this day

The U.S. Food and Drug Administration will require manufacturers of GLP-1 medicines to add warnings about a possible association with nonarteritic anterior ischemic optic neuropathy, a rare condition that can cause sudden vision loss. The agency’s November 9 announcement applies across the drug class, including semaglutide and tirzepatide products.

NAION occurs when reduced blood flow damages the optic nerve. It typically causes sudden, painless vision loss in one eye, which can be permanent. The FDA’s action follows research identifying a possible link between GLP-1 medicines and the condition, but the evidence does not establish that the drugs cause NAION.

In an analysis of 126 clinical trials, the FDA identified 15 probable cases. The agency calculated rates of 6.4 cases per 100,000 person-years among people taking GLP-1 medicines and 3.8 per 100,000 person-years in comparison groups. The figures indicate a small absolute risk, and do not resolve whether the medicines themselves, underlying health conditions or other factors explain the association.

The label change comes as health authorities and clinicians offer guidance on recognizing symptoms and making treatment...

Now playing
0:00 / 0:00